This retrospective study identified oligorecurrent prostate cancer patients with five or fewer nodal, bone, or visceral metastases detected by choline or PSMA-PET/CT who underwent SBRT, with or without systemic therapy, at eight tertiary cancer centers. The gene discussed is FOLH1; the disease is prostate carcinoma.